FG Onco Tamoxifen
Pharmacogenetics of tamoxifen treatment
Why undergoing this examination?
Tamoxifen is the most commonly used selective modulator in breast cancer treatment. One of the main causes of interindividual response differences to tamoxifen is the presence of alleles in the CYP2D6 gene associated with null, decreased, or increased enzymatic activity compared to normal. The CYP2D6 gene encodes the CYP2D6 enzyme, which converts tamoxifen into endoxifen, its active metabolite and the primary contributor to its anti-neoplastic activity. Consequently, a decrease in CYP2D6 enzyme activity results in reduced efficacy of tamoxifen treatment.
What is this exam?
The FG Onco Tamoxifen genetic profile studies the 11 main allelic variants of the CYP2D6 gene with known clinical relevance. These 11 allelic variants cover over 97% of all alleles described in this gene. The goal of the analysis is to identify patients with an increased likelihood of reduced tamoxifen treatment efficacy and the development of serious side effects.
For whom is it indicated?
- Patients undergoing pharmacological treatment that does not yield expected results;
- Patients experiencing drug-related side effects.
Technology
Next-generation sequencing (NGS).
FG Onco Tamoxifen
Pharmacogenetics of tamoxifen treatment
Tamoxifen is the most commonly used selective modulator in breast cancer treatment. One of the main causes of interindividual response differences to tamoxifen is the presence of alleles in the CYP2D6 gene associated with null, decreased, or increased enzymatic activity compared to normal. The CYP2D6 gene encodes the CYP2D6 enzyme, which converts tamoxifen into endoxifen, its active metabolite and the primary contributor to its anti-neoplastic activity. Consequently, a decrease in CYP2D6 enzyme activity results in reduced efficacy of tamoxifen treatment.
The FG Onco Tamoxifen genetic profile studies the 11 main allelic variants of the CYP2D6 gene with known clinical relevance. These 11 allelic variants cover over 97% of all alleles described in this gene. The goal of the analysis is to identify patients with an increased likelihood of reduced tamoxifen treatment efficacy and the development of serious side effects.
- Patients undergoing pharmacological treatment that does not yield expected results;
- Patients experiencing drug-related side effects.
Next-generation sequencing (NGS).
Advantages
SYNLAB GROUP
Guaranteed by the experience of the absolute European leader in laboratory diagnostics.
COMPLETE
Detailed report, where the results will suggest individualized courses of action, aiding in prognosis for greater treatment efficacy and a significant reduction in adverse reactions.
Extra Information
DOCUMENTATION – Available on the Extranet for clients
- Informed Consent;
- Clinical Questionnaire;
- Medical prescription.
PREPARATION
- Fasting is not necessary for the test.
Delivery Time
12 business days
Sample Type
5mL whole blood in EDTA
Other exams pharmacogenetics:
NEURO PGx
Genetic Analysis of Drug Response
GLOBAL PGx
Genetic Analysis of Drug Response
FG Onco Tamoxifen
Pharmacogenetics of tamoxifen treatment
FG Onco Lapatinib
Pharmacogenetics of lapatinib treatment
FG Cardio Arrhythmia
Pharmacogenetics of Arrhythmias
FG Cardio Hypertension
Pharmacogenetics of Arterial Hypertension
FG Neuro Anxiety
Pharmacogenetics of Anxiety Disorder
FG Neuro Depression
Pharmacogenetics of depressive disorder
FG Neuro Epilepsy
Pharmacogenetics of Epilepsies
FG Neuro Psychosis
Pharmacogenetics of Psychotic Disorders
FG Cardio Completo
Pharmacogenetics in Cardiology
FG Basic
Genetic Analysis of Drug Response